RecruitingPHASE1, PHASE2NCT05747261
Study of the Safety and Efficacy of an Adeno-Associated Viral Vector Carrying the SMN Gene After a Single Intravenous Administration of Escalating Doses in Children With Spinal Muscular Atrophy (BLUEBELL)
Studying Spinal Muscular Atrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Biocad
- Principal Investigator
- Arina V Zinkina-Orikhan, PhDDirector of Clinical Development Department, BIOCAD
- Intervention
- ANB-004, dose 1(genetic)
- Enrollment
- 40 enrolled
- Eligibility
- All sexes
- Timeline
- 2023 – 2030
Study locations (6)
- 1. State Institution Republican Scientific and Practical Center "Mother and Child", Minsk, Belarus
- Federal State Autonomous Educational Institution of Higher Education "N.I. Pirogov Russian National Research Medical University", Ministry of Health of the Russian Federation, Moscow, Russia
- Federal State Autonomous Institution "National Medical Research Center for Children's Health", Ministry of Health of the Russian Federation, Moscow, Russia
- Federal State Budgetary Educational Institution of Higher Education "St. Petersburg State Pediatric Medical University", Ministry of Health of the Russian Federation, Saint Petersburg, Russia
- Federal State Budgetary Institution "V. A. Almazov National Medical Research Center" of the Ministry of Health of the Russian Federation, Saint Petersburg, Russia
- State Autonomous Healthcare Institution of the Sverdlovsk Region "Regional Children's Clinical Hospital", Yekaterinburg, Russia
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05747261 on ClinicalTrials.govOther trials for Spinal Muscular Atrophy
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07488338HABIT-ILE + FST in Children With SMA: Preliminary EffectivenessTeachers College, Columbia University
- RECRUITINGNCT07400198Gait and Bone Health in SMAJacqueline Montes
- RECRUITINGPHASE1, PHASE2NCT07070999Study of Safety, Tolerability and Efficacy of GB221 in Infants With Spinal Muscular Atrophy Type 1Gemma Biotherapeutics
- RECRUITINGNANCT07321977Assessment of a Portable Digital Device for Quantified Analysis of Markerless Walking in Volunteers With Neuromuscular Diseases or Asymptomatic VolunteersInstitut de Myologie, France
- RECRUITINGPHASE2NCT07287982A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophyargenx
- RECRUITINGNANCT07286565Active NBS Study: Decentralised Monitoring Motor Development in Children With Duchenne Muscular Dystrophy or Spinal Muscular Atrophy Identified by Newborn ScreeningCentre Hospitalier Universitaire de Liege
- RECRUITINGNCT06532474Exploring the Physiologic, Pharmacodynamic, and Clinical Responses of Skeletal Muscle in Patients With Spinal Muscular Atrophy Treated With SMN-Directed TherapiesSt. Jude Children's Research Hospital
- RECRUITINGPHASE3NCT07265232Real World Clinical Effectiveness & Safety of Vesemnogene Lantuparvovec for Spinal Muscular Atrophy (SMA) in Low-middle Income Countries (LMIC).Lantu Biopharma